Table of Contents Author Guidelines Submit a Manuscript

Leishmaniasis: Current Scenario and Future Prospective for the Vaccine Development and Drug Therapy

Call for Papers

Leishmaniasis, a complex vector-borne parasitic disease, prevails throughout different geographical regions of the globe, but occurs more specifically in the tropics and subtropics of Africa, South and Central America, the Middle East, Southern Europe, and Asia. It ranks second among the tropical diseases in terms of mortality and considered as neglected tropical disease because of its strong association with poverty. According to latest reports compiled by the World Health Organization (WHO) and Centre for Diseases Control and Prevention (CDC), leishmaniasis spreads in nearly 88 countries and 350 million people are at risk and about 1.6 million new cases occur worldwide that leads to more than 50 thousand deaths annually.

Eliminating leishmaniasis has become very difficult despite of the many efforts and programs conducted for combating the disease. Controlling the sand-flies, the vector for the parasites, still remains a big challenge since they are increasingly resistant towards the insecticides used currently. Vaccination remains the most appropriate opportunity for the prevention and safe treatment of leishmaniasis but there is no licensed vaccine yet discovered. The current chemotherapy against leishmaniasis suffers from shortcomings such as toxicity, poor efficacy, limited accessibility due to high cost, and poor compliance. Additionally, the emergence of drug resistance, particularly toward pentavalent antimonials in the Indian subcontinent, and resurgence of VL with HIV as a coinfection have threatened to leave the existing chemotherapeutic agents. All these issues basically emphasize an urgent need for more research towards vaccine development and drug discovery efforts into leishmaniasis with the ultimate aim of finding the best solutions to combat the disease.

This special issue is aimed at highlighting the current development and progress in the leishmaniasis research. We welcome researchers to contribute their original research articles as well as review articles addressing the recent developments of the vaccine research and advances in drug development and treatment.

Potential topics include but are not limited to the following:

  • Drug resistance against leishmaniasis and its current status
  • New antileishmanial drug treatment and strategies
  • Investigations into new lead compounds and drug candidates against leishmaniasis
  • Current antileishmanial drug regimens
  • Vaccine development and potential vaccine candidates against leishmaniasis
  • Screening for potential antileishmanial agents from natural sources
  • Critical reviews or evaluations on the current drug treatment, drug design, and vaccine design

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 25 May 2018
Publication DateOctober 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Guest Editors